Glycomine Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $33M
Latest Deal Amount
  • Investors
  • 11

Glycomine General Information

Description

Provider of nanomedicines designed to develop a new generation of replacement therapies for rare diseases. The company's medicines include orphan drugs that combine replacement therapies such as substrates, enzymes and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to treat efficiently their patients with serious rare monogenic disorders of metabolism and protein misfolding.

Contact Information

Website
www.glycomine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Biotechnology
Primary Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycomine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 07-Aug-2019 $33M 000.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 16-Nov-2016 0000 000.00 000.00 Completed Startup
2. Accelerator/Incubator 01-Jan-2016 $630K $630K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Glycomine’s complete valuation and funding history, request access »

Glycomine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 1,337,056 $0.000100 $3.8 $3.8 1x $3.8 2%
To view Glycomine’s complete cap table history, request access »

Glycomine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of nanomedicines designed to develop a new generation of replacement therapies for rare diseases. The company's
Drug Discovery
San Carlos, CA
6 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

0000 000

ncididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullam
0000 000000000
London, United Kingdom
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

00000000

ua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 00000000
Boston, MA
000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glycomine Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MiNA Therapeutics Venture Capital-Backed London, United Kingdom 00 000.00 00000000000 000.00
00000000 Venture Capital-Backed Boston, MA 000 00.000 000000000 00.000
0000000 0000000000 Formerly VC-backed London, United Kingdom 00 00000 000000000 00000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000000 00000
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
You’re viewing 5 of 21 competitors. Get the full list »

Glycomine Executive Team (4)

Name Title Board Seat Contact Info
Peter McWilliams Ph.D Chief Executive Officer & Board Member
Matt Wilsey Advisor
Horacio Plotkin MD Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Glycomine Board Members (6)

Name Representing Role Since
Christopher Starr Ph.D Self Chairman 000 0000
Kenneth Harrison Ph.D Novo Holdings Board Member 000 0000
Peter McWilliams Ph.D Glycomine Chief Executive Officer & Board Member 000 0000
Timothy Mills Ph.D Glycomine Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Glycomine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycomine Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asahi Kasei Pharma America Corporation Minority 000 0000 000000 0
Mission Bay Capital Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
Chiesi Ventures Corporate Venture Capital Minority 000 0000 000000 0
John Griffin Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial